Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.

@article{Lafontan2007EffectsOC,
  title={Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.},
  author={Max Lafontan and Pier Vincenzo Vincenzo Piazza and J Girard},
  journal={Diabetes & metabolism},
  year={2007},
  volume={33 2},
  pages={85-95}
}
Clinical reports (RIO trials) have shown that chronic administration of a CB-cannabinoid receptor antagonist (rimonabant) provides improvements of disturbed metabolic parameters observed in overweight and obese patients with type 2 diabetes. The production of endocannabinoid and the expression of CB1-cannabinoid receptors are largely distributed in the different organs aside from the brain. It is now clearly established that endocannabinoids act both through orexigenic effects and peripheral… CONTINUE READING